Nicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox's lead program in clinical development is bimatoprost grenod (NCX 470), a novel nitric oxide-donating bimatoprost eye drop, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Nicox SA generates revenue from VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, and ZERVIATE® in allergic conjunctivitis, licensed in multiple geographies, including to Harrow, Inc. in the United States, and Ocumension Therapeutics in the Chinese and in the majority of Southeast Asian markets.

Employees

Sector

Pharmaceuticals

More about the company

Market Cap	34.06M 39.18M 31.7M 29.11M 54.97M 3.74B 55.82M 374M 147M 1.86B 147M 144M 6.24B	P/E 2026 *	-5.52x	P/E 2027 *	38.7x
Enterprise Value	34.06M 39.18M 31.7M 29.11M 54.97M 3.74B 55.82M 374M 147M 1.86B 147M 144M 6.24B	EV / Sales 2026 *	11.4x	EV / Sales 2027 *	3.41x
Free-Float	99.65%	Yield 2026 *	-	Yield 2027 *	-

Jul. 01	Nicox Submits NCX 470 New Drug Application In The United States	CI
Jul. 01	Nicox files U.S. marketing approval application
Jun. 23	Nicox Bags EUR6 Million Shareholder Loan	MT
Jun. 23	Nicox Secures Backing From a Shareholder and Financial Partner
Jun. 18	Nicox Receives Positive Feedback from China
Jun. 18	Nicox Announces Positive Pre-Submission Regulatory Feedback in China Supporting NDA Filing for NCX 470	CI
Apr. 29	Nicox S.A. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
Feb. 24	Nicox SA Highlights Positive NCX 470 Phase 3 Data Confirming Therapeutic Profile at the 2026 American Glaucoma Society Annual Meeting	CI
Feb. 24	Edenred, Forvia, Freelance.com... Key Stocks to Watch Today in Paris -
Feb. 24	Nicox Reports Positive Phase 3 Results for NCX 470
Feb. 16	Nicox, Sanofi, Valneva... Stocks to Watch Today in Paris
Feb. 16	Nicox Moves Forward with U.S. Health Authorities for Its NCX 470
Jan. 05	Nicox Strengthens Its Financial Position

Jul. 01	Nicox’s NCX 470 New Drug Application Submitted in the United States by Kowa, with Associated €3 million Milestone Payment	GL
Jun. 23	Nicox and Vester Finance Sign Shareholder Loan Agreement to Support Strategic Activities for the Company	GL
Jun. 18	Nicox Announces Positive Pre-submission Regulatory Feedback in China Supporting NDA filing for NCX 470	GL
Jun. 08	Reminder: Nicox June 2024 Warrants will expire June 19, 2026	GL
Jun. 03	Nicox: Notice of the Ordinary and Extraordinary Shareholders’ Meeting on June 24, 2026 and appointment of an ad hoc representative	GL

Jul. 01	Bourse : Schneider se renforce dans l'IA, Air Liquide investit pour SK Hynix, Nike déçoit
Jul. 01	Nicox dépose une demande d'autorisation de mise sur le marché aux Etats-Unis
Jul. 01	La Bourse s'habitue à tout
Jul. 01	Nicox : Demande d’autorisation de mise sur le marché de NCX 470 soumise aux Etats-Unis par Kowa, avec un paiement d’étape de 3 millions d’euros associé
Jun. 23	Bourse : Sanofi enchaîne les AMM, Prysmian enchaîne les contrats, l'IA enchaîne les dépenses

Manager	Title	Age	Since
Gavin Spencer CEO	Chief Executive Officer	55	2024-02-27
Sandrine Gestin DFI	Director of Finance/CFO	58	2014-12-31
Doug Hubatsch CTO	Chief Tech/Sci/R&D Officer	-	2021-12-12

NICOX Stock Swiss Exchange

Stocks

OXCOX

FR0000074130

Pharmaceuticals

Valuation: NICOX

Latest news : NICOX

Press Releases: NICOX

News in other languages: NICOX

Managers and Directors: NICOX

Specialty & Advanced Pharmaceuticals

Financials

Company Profile

Director	Title	Age	Since
Gavin Spencer BRD	Director/Board Member	55	2024-04-07
Damian Marron CHM	Chairman	64	2024-07-15
Marc Bozec BRD	Director/Board Member	-	2024-07-15

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
NICOX	-.--%	-.--%	-	-	39.18M
MERCK & CO., INC.	+0.32%	-0.66%	+64.21%	+23.18%	322B
MERCK KGAA	+0.21%	+2.87%	+33.60%	-10.00%	71.6B
HALOZYME THERAPEUTICS, INC.	-0.91%	+0.74%	+39.85%	+92.63%	9.79B
KYOWA KIRIN CO., LTD.	-3.41%	-7.27%	-3.78%	-9.28%	8.39B
SK BIOPHARMACEUTICALS CO., LTD.	+1.80%	-1.99%	-15.78%	-13.19%	4.3B
YUHAN CORPORATION	-0.68%	-1.87%	-34.78%	+6.01%	3.81B
BETTA PHARMACEUTICALS CO., LTD.	+3.08%	-1.41%	-12.94%	+15.81%	3.58B
SUPERNUS PHARMACEUTICALS, INC.	-2.15%	-3.40%	+25.70%	+41.55%	2.59B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+0.85%	+9.88%	-0.25%	-3.21%	2.25B
Average	-0.09%	-0.34%	+10.65%	+15.94%	47.54B
Weighted average by Cap.	+0.22%	-0.09%	+54.29%	+17.97%

	2026 *	2027 *
Net sales	3M 3.45M 2.79M 2.56M 4.84M 329M 4.92M 32.91M 12.92M 164M 12.96M 12.68M 550M	10M 11.5M 9.31M 8.55M 16.14M 1.1B 16.39M 110M 43.06M 547M 43.2M 42.25M 1.83B
Net income	-6M -6.9M -5.58M -5.13M -9.68M -659M -9.83M -65.83M -25.84M -328M -25.92M -25.35M -1.1B	1M 1.15M 931K 855K 1.61M 110M 1.64M 10.97M 4.31M 54.67M 4.32M 4.23M 183M
Net Debt	-	-